secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001842952-22-000104
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics nominates CTIM-76 as lead CLDN6 bispecific; IND expected Q1 2024
--------------------------------------------------------------------------------

- CTIM-76 is a CLDN6 x CD3 bispecific antibody with silenced Fc to reduce aberrant T-cell activation.
- IND submission for CTIM-76 planned for Q1 2024 to the FDA.
- Targets CLDN6-positive solid tumors including ovarian, endometrial, testicular, and gastric cancers.
- Preclinical data show potent lysis of CLDN6+ cancer cells with minimal free cytokine release.
- Collaboration with Integral Molecular; webinar on December 1, 2022, at 11 a.m. ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000104/0001842952-22-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000104/cntx-20221129.htm
  HTML page:      https://secwatch.observer/filing/0001842952-22-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer